An Approach to the Estimation of the Risk of TTP During Clopidogrel Therapy

Stroke

Volumn 35, Issue 2, 2004, Pages 537-538

  Jonas, Saran ^a   Grieco, Giacinto ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOPIDOGREL; ANTITHROMBOCYTIC AGENT; DRUG DERIVATIVE; TICLOPIDINE;

ANTICOAGULANT THERAPY; DOSE RESPONSE; DRUG MARKETING; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; FOOD AND DRUG ADMINISTRATION; HUMAN; NOTE; PRIORITY JOURNAL; RISK FACTOR; THROMBOTIC THROMBOCYTOPENIC PURPURA; CHEMICALLY INDUCED DISORDER; DRUG UTILIZATION; INCIDENCE; POSTMARKETING SURVEILLANCE; RISK ASSESSMENT; STATISTICS; UNITED STATES;

DRUG UTILIZATION; HUMANS; INCIDENCE; PLATELET AGGREGATION INHIBITORS; PRODUCT SURVEILLANCE, POSTMARKETING; PURPURA, THROMBOTIC THROMBOCYTOPENIC; RISK ASSESSMENT; TICLOPIDINE; UNITED STATES;

EID: 1642586936     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/str.35.2.537     Document Type: Note

References (3)

1. Zakarija A et al. Clopidogrel-associated thrombotic thrombocytopenic purpura (TTP): An update of pharmacovigilance efforts conducted by independent researchers, the pharmaceutical suppliers, and the Food and Drug Administration. Stroke. 2004;35:533-538.
2. Donnan GA, Davis SM. Neurologist, internist, or strokologist? Stroke. 2003;34:2765.
3. CAPRIE Steering Committee. A randomized, blinded, trial of clopidogrel vs. aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996;348:1329-1339.